Critically, TPD52L2 upregulation in oxaliplatin-resistant GC models drives chemoresistance, whereas TPD52L2 suppression reverses this phenotype, suggesting actionable targets to overcome multidrug resistance. Here, TPD52L2 is linked to gastric cancer.